Phase II study of inhaled liposomal amikacin (Arikace) in cystic fibrosis patients with respiratory tract infections due to Pseudomonas aeruginosa

Trial Profile

Phase II study of inhaled liposomal amikacin (Arikace) in cystic fibrosis patients with respiratory tract infections due to Pseudomonas aeruginosa

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2010

At a glance

  • Drugs Amikacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Transave
  • Most Recent Events

    • 18 Jun 2010 Status changed from recruiting to completed.
    • 18 Jun 2010 Results of the open-label extension of this trial have been presented at the 33rd European Cystic Fibrosis Society (ECFS), according to a Transave media release.
    • 19 May 2010 Results presented at the 106th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top